Related Experiment Video
Updated: May 13, 2025

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines
Published on: April 21, 2022
Malignant Pleural Mesothelioma: From Pathophysiology to Innovative Actionable Targets
Francesco Rocco Bertuccio1,2, Simone Montini1,2, Maria Antonietta Fusco1,2
1Department of Internal Medicine and Medical Therapeutics, University of Pavia Medical School, 27100 Pavia, Italy.
Background:
Pleural mesothelioma (PM) is a rare and highly aggressive cancer which arises from mesothelial layer and primarily linked to asbestos exposure, genetic predispositions, and specific mutations. Despite current treatment modalities, including chemotherapy, antiangiogenic therapy and more recently immunotherapy, the prognosis remains dismal, with a median survival time of 6-18 months.
Objectives:
The urgent need for novel therapeutic strategies has prompted research into molecular targets and precision medicine approaches. At present, many potential targets for therapeutic strategies have been identified, and emerging clinical trials are demonstrating certain clinical efficacy.
Methods:
This review examines advancements in understanding PM's genetic and epigenetic landscape, signaling pathways, and promising therapeutic targets.
Results:
We also discuss the results of recent clinical trials and their potential implications for future treatment paradigms.
More Related Videos
Related Concept Videos
Pleural Disorders: Types and Brief Description
Targeted Cancer Therapies
There are several types of targeted therapies against...
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
The Tumor Microenvironment
Mitogens and the Cell Cycle
mTOR Signaling and Cancer Progression
The mTOR pathway or the...

